<SEC-DOCUMENT>0001157523-21-001128.txt : 20210908
<SEC-HEADER>0001157523-21-001128.hdr.sgml : 20210908
<ACCEPTANCE-DATETIME>20210908082822
ACCESSION NUMBER:		0001157523-21-001128
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210908
FILED AS OF DATE:		20210908
DATE AS OF CHANGE:		20210908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		211240785

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52488008.htm
<DESCRIPTION>IMMUNOPRECISE ANTIBODIES LTD. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED
      STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES
      AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM
      6-K</div>
    <div style="font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; font-weight: bold;">&#160;</div>
    <div style="text-align: center;">For the month of September 2021</div>
    <div style="text-align: center;">&#160;</div>
    <div style="text-align: center;">Commission File Number: <font style="font-weight: bold;">001-39530</font></div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">ImmunoPrecise
      Antibodies Ltd.</div>
    <div style="text-align: center;">(Translation of registrant&#8217;s name into English)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8</div>
    <div style="text-align: center;">(Address of principal executive office)</div>
    <div>&#160;</div>
    <div style="text-align: justify;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div><br>
    </div>
    <div style="text-align: center;">Form 20-F&#160; <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Form 40-F&#160; <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: justify;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div style="font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
    </div>
    &#160;<br>
    <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="text-align: center;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zec420e39632f4f819309b6f2abb6b3ff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 11.54%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 1.54%; vertical-align: bottom;">
            <div>&#160;</div>
          </td>
          <td style="width: 86.92%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.54%; vertical-align: top;">
            <div><a href="a52488008ex99_1.htm">99.1</a></div>
          </td>
          <td style="width: 1.54%; vertical-align: bottom;">
            <div>&#160;</div>
          </td>
          <td style="width: 86.92%; vertical-align: bottom;">
            <div style="text-align: justify;"><a href="a52488008ex99_1.htm">Press Release dated
                September 8, 2021.</a></div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>&#160;</div>
    <br>
    <div style="text-align: center; font-weight: bold;">SIGNATURE</div>
    <div style="text-align: center; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 24pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
      behalf by the undersigned, thereunto duly authorized.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb5115a79c19c4dec961737bbe9029321" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36.54%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 13.4%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.06%; vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">IMMUNOPRECISE ANTIBODIES LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36.54%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 13.4%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 3.92%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 46.14%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36.54%; vertical-align: top;">
            <div>Date: September 8, 2021</div>
          </td>
          <td style="width: 13.4%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 3.92%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 46.14%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="font-style: italic;">/s/ Lisa Helbling</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36.54%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 13.4%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 3.92%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 46.14%; vertical-align: top;">
            <div>Lisa Helbling</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36.54%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 13.4%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 3.92%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 46.14%; vertical-align: top;">
            <div>Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify;">&#160;</div>
    <br>
    <div>&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52488008ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <table cellspacing="0" cellpadding="0" border="0" id="z41f40af4bba5463783eb50a30a6a1671" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 100%; text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>ImmunoPrecise&#8217;s Dutch Subsidiary </b><b>Receives French Research Tax Credit (CIR) Accreditation</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>VICTORIA, British Columbia--(BUSINESS WIRE)--September 8, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the &#8220;Company&#8221; or &#8220;IPA&#8221;) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today
            that its site in Oss, the Netherlands, which is part of the Company&#8217;s subsidiary, IPA Europe, has been granted a three-year approval for the &#8220;Cr&#233;dit d'Imp&#244;t Recherche&#8221; (CIR) from the French Ministry of Higher Education and Research. CIR is a
            French R&amp;D tax credit initiative which will provide tax credits to eligible French companies when they engage IPA Europe, Oss, in qualified research and development activities. </p>
          <p> <b>The CIR rate that an eligible French customer purchasing services from IPA Europe may receive varies depending on the amount invested: </b> </p>
          <ul style="list-style-type: disc;">
            <li> 30% for eligible R&amp;D expenses up to &#8364;100 million of R&amp;D activities, 5% above that amount </li>
            <li> 20% for eligible innovation expenditure (for SMEs only) of up to &#8364;400,000 </li>
          </ul>
          <p> <b>An Added Benefit to the Full-Service Advantage of IPA</b> </p>
          <p> Dr Stefan Lang, Chief Business Officer of IPA, commented: &#8220;We are pleased to offer this accreditation to eligible French companies who engage with IPA in Oss in fundamental and applied research and experimental development activities. IPA is
            privileged to be able to pass this recognition of our role in research and innovation in scientific antibody discovery in Europe, onto existing and new French partners, in the form of tax relief.&#8221; </p>
          <p> <b>About CIR</b> </p>
          <p> For more information about the French CIR R&amp;D tax credit initiative, go to: <br>
            https://www.impots.gouv.fr/portail/international-professionnel/tax-incentives </p>
          <p> https://www.enseignementsup-recherche.gouv.fr/cid114521/guide-du-credit-d-impot-recherche-2020.html </p>
          <p> <b>ImmunoPrecise Antibodies Ltd.</b> </p>
          <p> ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform
            the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For
            further information, visit www.immunoprecise.com. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Forward Looking Information</b> </p>
          <p> This news release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as &#8220;potential&#8221;,
            &#8220;plans&#8221;, &#8220;expects&#8221; or &#8220;does not expect&#8221;, &#8220;is expected&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;, &#8220;anticipates&#8221; or &#8220;does not anticipate&#8221;, or &#8220;believes&#8221;, or variations of such words and phrases or state that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;,
            &#8220;would&#8221;, &#8220;might&#8221; or &#8220;will&#8221; be taken, occur or be achieved. Forward-looking information contained in this news release include, but are not limited to, statements regarding the potential availability or benefit of the French CIR tax credit to
            IPA Europe&#8217;s customers. In respect of the forward-looking information contained herein, the Company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. </p>
          <p> Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or
            achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, whether changes to the French CIR tax credit program,
            as well as those risks discussed in the Company&#8217;s Annual Information Form dated July 27, 2021 (which may be viewed on the Company&#8217;s profile at www.sedar.com) and the Company&#8217;s Form 40-F dated July 27, 2021 (which may be viewed on the Company&#8217;s
            profile at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from
            those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking information contained in this news release. </p>
          <p> The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking
            statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. </p>
          <p> Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Investor contact: </b><br>
            LifeSci Advisors <br>
            John Mullaly <br>
            Email: jmullaly@lifesciadvisors.com </p>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
